JP7725041B2 - コラーゲン結合型膜透過性ペプチド、並びに、該ペプチド及びコラーゲン若しくはコラーゲン誘導体を含む運搬体 - Google Patents

コラーゲン結合型膜透過性ペプチド、並びに、該ペプチド及びコラーゲン若しくはコラーゲン誘導体を含む運搬体

Info

Publication number
JP7725041B2
JP7725041B2 JP2025502805A JP2025502805A JP7725041B2 JP 7725041 B2 JP7725041 B2 JP 7725041B2 JP 2025502805 A JP2025502805 A JP 2025502805A JP 2025502805 A JP2025502805 A JP 2025502805A JP 7725041 B2 JP7725041 B2 JP 7725041B2
Authority
JP
Japan
Prior art keywords
collagen
seq
domain
membrane
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2025502805A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2025023312A1 (https=
JPWO2025023312A5 (https=
Inventor
賢司 井手
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koken Co Ltd
Original Assignee
Koken Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koken Co Ltd filed Critical Koken Co Ltd
Publication of JPWO2025023312A1 publication Critical patent/JPWO2025023312A1/ja
Publication of JPWO2025023312A5 publication Critical patent/JPWO2025023312A5/ja
Application granted granted Critical
Publication of JP7725041B2 publication Critical patent/JP7725041B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M1/00—Apparatus for enzymology or microbiology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Sustainable Development (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
JP2025502805A 2023-07-26 2024-07-25 コラーゲン結合型膜透過性ペプチド、並びに、該ペプチド及びコラーゲン若しくはコラーゲン誘導体を含む運搬体 Active JP7725041B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023121675 2023-07-26
JP2023121675 2023-07-26
PCT/JP2024/026723 WO2025023312A1 (ja) 2023-07-26 2024-07-25 コラーゲン結合型膜透過性ペプチド、並びに、該ペプチド及びコラーゲン若しくはコラーゲン誘導体を含む運搬体

Publications (3)

Publication Number Publication Date
JPWO2025023312A1 JPWO2025023312A1 (https=) 2025-01-30
JPWO2025023312A5 JPWO2025023312A5 (https=) 2025-07-01
JP7725041B2 true JP7725041B2 (ja) 2025-08-19

Family

ID=94375490

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025502805A Active JP7725041B2 (ja) 2023-07-26 2024-07-25 コラーゲン結合型膜透過性ペプチド、並びに、該ペプチド及びコラーゲン若しくはコラーゲン誘導体を含む運搬体

Country Status (2)

Country Link
JP (1) JP7725041B2 (https=)
WO (1) WO2025023312A1 (https=)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008067717A (ja) 2001-06-20 2008-03-27 Dainippon Sumitomo Pharma Co Ltd 核酸導入を促進させる方法
JP2014210730A (ja) 2013-04-18 2014-11-13 株式会社高研 細胞膜透過性ペプチドを付加したコラーゲン又はコラーゲン誘導体を含む運搬体
WO2016068228A1 (ja) 2014-10-29 2016-05-06 株式会社高研 薬剤徐放担体及び薬剤徐放方法
WO2016199674A1 (ja) 2015-06-11 2016-12-15 学校法人慶應義塾 融合タンパク質又は複合タンパク質、細胞内送達用担体、部分ペプチド、細胞膜透過促進剤、ｄｎａ、及びベクター
JP2019534922A (ja) 2016-10-04 2019-12-05 コーネル ユニヴァーシティー 潤滑性ブロックコポリマーおよび生体模倣境界潤滑剤としてのそれらの使用
JP2020526493A (ja) 2017-07-07 2020-08-31 サイミック アイピー， エルエルシー 化学的に修飾された主鎖を有するバイオコンジュゲート
WO2022125673A1 (en) 2020-12-09 2022-06-16 Fred Hutchinson Cancer Research Center Cell-penetrating peptides and peptide complexes and methods of use
WO2023090381A1 (ja) 2021-11-18 2023-05-25 ピューロテックバイオ株式会社 宿主因子ｄｏｃｋ１１をターゲットとした抗ｂ型肝炎ウイルス剤

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008067717A (ja) 2001-06-20 2008-03-27 Dainippon Sumitomo Pharma Co Ltd 核酸導入を促進させる方法
JP2014210730A (ja) 2013-04-18 2014-11-13 株式会社高研 細胞膜透過性ペプチドを付加したコラーゲン又はコラーゲン誘導体を含む運搬体
WO2016068228A1 (ja) 2014-10-29 2016-05-06 株式会社高研 薬剤徐放担体及び薬剤徐放方法
WO2016199674A1 (ja) 2015-06-11 2016-12-15 学校法人慶應義塾 融合タンパク質又は複合タンパク質、細胞内送達用担体、部分ペプチド、細胞膜透過促進剤、ｄｎａ、及びベクター
JP2019534922A (ja) 2016-10-04 2019-12-05 コーネル ユニヴァーシティー 潤滑性ブロックコポリマーおよび生体模倣境界潤滑剤としてのそれらの使用
JP2020526493A (ja) 2017-07-07 2020-08-31 サイミック アイピー， エルエルシー 化学的に修飾された主鎖を有するバイオコンジュゲート
WO2022125673A1 (en) 2020-12-09 2022-06-16 Fred Hutchinson Cancer Research Center Cell-penetrating peptides and peptide complexes and methods of use
WO2023090381A1 (ja) 2021-11-18 2023-05-25 ピューロテックバイオ株式会社 宿主因子ｄｏｃｋ１１をターゲットとした抗ｂ型肝炎ウイルス剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
田苗見 綾 他，アテロコラーゲン結合型膜透過性ペプチドの開発とそのメカニズム解析，第３６回日本ＤＤＳ学会学術集会プログラム予稿集，2020年08月10日，Ｐ－６５
藤本 一朗 他，核酸デリバリーにおけるアテロコラーゲンと種々の機能性ペプチドのメカニズム解析，第３７回日本ＤＤＳ学会学術集会プログラム予稿集，2021年06月07日，Ｐ－１３３

Also Published As

Publication number Publication date
WO2025023312A1 (ja) 2025-01-30
JPWO2025023312A1 (https=) 2025-01-30

Similar Documents

Publication Publication Date Title
Raymond et al. Multicomponent peptide assemblies
KR101317100B1 (ko) 세포-침투성 펩티드로서 유용한 펩티드
US9358308B2 (en) Compositions of a peptide targeting system for treating cancer
JP2022101618A (ja) 条件的活性型ポリペプチド
JP5858285B2 (ja) キャリアペプチドフラグメント及びその利用
KR102585956B1 (ko) 조건부 활성 폴리펩티드 및 이를 제조하는 방법
Unzueta et al. Release of targeted protein nanoparticles from functional bacterial amyloids: A death star-like approach
IL265920B1 (en) Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
RS58839B1 (sr) Muteini lipokalina u suzama koji vezuju il-4 r alfa
JP2014508515A (ja) Ｃｘｃｒ４細胞に治療分子を効率的かつ選択的に送達するための方法および試薬
WO2014026054A2 (en) CD20 scFv-ELPs METHODS AND THERAPEUTICS
Falanga et al. Hydrophobicity: The door to drug delivery
CN109563151A (zh) 用于治疗癌症的方法和组合物
JPWO2005014625A1 (ja) 脳移行活性を有するポリペプチド、およびその利用
Ma et al. Peptide-based coacervates in therapeutic applications
US10259852B2 (en) Conjugate comprising P21 protein for the treatment of cancer
CN106795205A (zh) 新细胞膜穿透肽及其作为生物活性物质传递体的用途
US12186408B2 (en) Fusion polypeptides for inhibiting angiogenesis, fusion protein nanocages having multivalent peptides for inhibiting angiogenesis, and theranostic use thereof
JP7725041B2 (ja) コラーゲン結合型膜透過性ペプチド、並びに、該ペプチド及びコラーゲン若しくはコラーゲン誘導体を含む運搬体
Wang et al. QKCMP peptide carrier macromolecule structure and release system based on triangular DNA origami nanostructures: A novel strategy for promoting angiogenesis
JP2014210730A (ja) 細胞膜透過性ペプチドを付加したコラーゲン又はコラーゲン誘導体を含む運搬体
KR102934900B1 (ko) Lag3 결합 펩타이드를 융합한 페리틴 나노케이지 및 이의 항암면역치료제로서의 용도
KR102726136B1 (ko) Pd-l1 결합 펩타이드 2를 융합한 페리틴 나노케이지 및 이의 항암면역치료제로서의 용도
Rahman et al. Peptide-based anticancer targeted therapeutics: state of the art
Yuan et al. Engineered Elastin‐Like Polypeptides: Intelligent Self‐Assembling Platforms for Biomedical Application

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250325

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250627

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250711

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250729

R150 Certificate of patent or registration of utility model

Ref document number: 7725041

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150